Gut microbiota disorders cause type 2 diabetes mellitus and homeostatic disturbances in gut-related metabolism in Japanese subjects

Adachi, Kazunori; Sugiyama, Tomoya; Yamaguchi, Yoshiharu; Tamura, Yasuhiro; Izawa, Shinya; Hijikata, Yasutaka; Ebi, Masahide; Funaki, Yasushi; Ogasawara, Nagahisa; Goto, Chiho; Sasaki, Makoto; Kasugai, Kunio

doi:10.3164/jcbn.18-101

Cited by 54 publications

(39 citation statements)

References 38 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, the abundance of the Bacteroidetes phylum was significantly decreased in patients with HT, HL, T2D, and comorbid conditions. In agreement with our results, Adachi et al demonstrated that T2D patients had larger and smaller fecal populations of Bifidobacterium and Bacteroides , respectively, than the control individuals [ 22 ]. Interestingly, they also demonstrated that T2D patients had consumed more carbohydrates and had lower fecal propionate and butyrate concentrations, and that the levels of Bifidobacterium were negatively correlated with the carbohydrate intake.…”

Section: Discussionsupporting

confidence: 93%

Changes in the Gut Microbiota are Associated with Hypertension, Hyperlipidemia, and Type 2 Diabetes Mellitus in Japanese Subjects

et al. 2020

View full text Add to dashboard Cite

The human gut microbiota is involved in host health and disease development. Therefore, lifestyle-related diseases such as hypertension (HT), hyperlipidemia (HL), and type 2 diabetes mellitus (T2D) may alter the composition of gut microbiota. Here, we investigated gut microbiota changes related to these diseases and their coexistence. This study involved 239 Japanese subjects, including healthy controls (HC). The fecal microbiota was analyzed through the isolation of bacterial genomic DNA obtained from fecal samples. Although there were no significant differences in the microbial structure between groups, there was a significant difference in the α-diversity between HC and the patients in whom two diseases coexisted. Moreover, Actinobacteria levels were significantly increased, whereas Bacteroidetes levels were significantly decreased in all disease groups. At the genus level, Bifidobacterium levels were significantly increased in the HL and T2D groups, as were those of Collinsella in all disease groups. In contrast, Alistipes levels were significantly lower in the HL group. Furthermore, metabolic enzyme families were significantly increased in all disease groups. Interestingly, the structure and function of the gut microbiota showed similar profiles in all the studied diseases. In conclusion, several changes in the structure of the gut microbiota are associated with T2D, HT, and HL in Japanese subjects.

show abstract

Section: Discussionsupporting

confidence: 93%

Changes in the Gut Microbiota are Associated with Hypertension, Hyperlipidemia, and Type 2 Diabetes Mellitus in Japanese Subjects

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We found no difference in our predictions between Control and Obese groups for propionate metabolism again in contrast to the predictions of Jiao et al [18] but consistent with the predictions of Lee and Ko [30] who found an improvement in metabolic parameters and increased propionate in metformin administered mice on a high fat diet. Our results for predictions on butyrate and propionate are also in accord with a chemical study of human subjects and both of these short chain fatty acids were decreased in faecal material from patients with T2D [31].…”

Section: Discussionsupporting

confidence: 89%

Characterisation of gut microbiota of obesity and type 2 diabetes in a rodent model

Ibrahim

Bourwis

Dolan

et al. 2021

Bioscience of Microbiota, Food and Health

View full text Add to dashboard Cite

Various studies have suggested that the gut microbiome interacts with the host and may have a significant role in the aetiology of obesity and Type 2 Diabetes (T2D). It was hypothesised that bacterial communities in obesity and T2D differ from control and compromise normal interactions between host and microbiota. Obesity and T2D were developed in rats by feeding a high-fat diet or a high-fat diet plus a single low-dose streptozotocin administration, respectively. The microbiome profiles and their metabolic potentials were established by metagenomic 16S rRNA sequencing and bioinformatics. Taxonomy and predicted metabolism-related genes in obesity and T2D were markedly 2 different from controls and indeed from each other. Diversity was reduced in T2D but not in Obese rats. Factors likely to compromise host intestinal, barrier integrity were found in Obese and T2D rats including predicted, decreased bacterial butyrate production. Capacity to increase energy extraction via ABC-transporters and carbohydrate metabolism were enhanced in Obese and T2D rats. T2D was characterized by increased proinflammatory molecules. While obesity and T2D show distinct differences, results suggest that in both conditions Bacteroides and Blautia species were increased indicating a possible mechanistic link.

show abstract

“…Thus, it would be an over simplification to consider the overall level of SCFAs as either good or bad for host metabolic health. There are significant changes in fecal bacterial compositions of T2D vs. healthy individuals [25], with a~30% decrease in fecal contents of propionate and butyrate in T2D subjects [26]. On the other hand, higher fecal concentration of SCFAs is associated with metabolic risk factors including adiposity, waist circumference, and homeostatic model assessment (HOMA) index [27].…”

Section: Scfas Serve As Energy Substrates Especially For Colonocytesmentioning

confidence: 99%

Controversial Roles of Gut Microbiota-Derived Short-Chain Fatty Acids (SCFAs) on Pancreatic β-Cell Growth and Insulin Secretion

Liu

Segovia

Yuan

et al. 2020

IJMS

View full text Add to dashboard Cite

In the past 15 years, gut microbiota emerged as a crucial player in health and disease. Enormous progress was made in the analysis of its composition, even in the discovery of novel species. It is time to go beyond mere microbiota-disease associations and, instead, provide more causal analyses. A key mechanism of metabolic regulation by the gut microbiota is through the production of short-chain fatty acids (SCFAs). Acting as supplemental nutrients and specific ligands of two G-protein-coupled receptors (GPCRs), they target the intestines, brain, liver, and adipose tissue, and they regulate appetite, energy expenditure, adiposity, and glucose production. With accumulating but sometimes conflicting research results, key questions emerged. Do SCFAs regulate pancreatic islets directly? What is the effect of β-cell-specific receptor deletions? What are the mechanisms used by SCFAs to regulate β-cell proliferation, survival, and secretion? The receptors FFA2/3 are normally expressed on pancreatic β-cells. Deficiency in FFA2 may have caused glucose intolerance and β-cell deficiency in mice. However, this was contrasted by a double-receptor knockout. Even more controversial are the effects of SCFAs on insulin secretion; there might be no direct effect at all. Unable to draw clear conclusions, this review reveals some of the recent controversies.

show abstract

Gut microbiota disorders cause type 2 diabetes mellitus and homeostatic disturbances in gut-related metabolism in Japanese subjects

Cited by 54 publications

References 38 publications

Changes in the Gut Microbiota are Associated with Hypertension, Hyperlipidemia, and Type 2 Diabetes Mellitus in Japanese Subjects

Changes in the Gut Microbiota are Associated with Hypertension, Hyperlipidemia, and Type 2 Diabetes Mellitus in Japanese Subjects

Characterisation of gut microbiota of obesity and type 2 diabetes in a rodent model

Controversial Roles of Gut Microbiota-Derived Short-Chain Fatty Acids (SCFAs) on Pancreatic β-Cell Growth and Insulin Secretion

Contact Info

Product

Resources

About